{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:53:26Z","timestamp":1761922406605,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021533","name":"Morrison Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"National Institutes of Health Office of the Director","doi-asserted-by":"publisher","award":["1S10OD030332"],"award-info":[{"award-number":["1S10OD030332"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["2K12GM111726"],"award-info":[{"award-number":["2K12GM111726"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ijpddr.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T02:24:54Z","timestamp":1675045494000},"page":"65-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7818-0238","authenticated-orcid":false,"given":"Katalin","family":"Toth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevan","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0070-4924","authenticated-orcid":false,"given":"Stanton F.","family":"McHardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8316-8559","authenticated-orcid":false,"given":"Philip T.","family":"LoVerde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3154-4775","authenticated-orcid":false,"given":"Michael D.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2023.01.003_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005942","article-title":"Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model","volume":"11","author":"Abla","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4269\/ajtmh.2006.74.342","article-title":"Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection","volume":"74","author":"Alonso","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0001-706X(00)00122-4","article-title":"The global status of schistosomiasis and its control","volume":"77","author":"Chitsulo","year":"2000","journal-title":"Acta Trop."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib5","first-page":"1","article-title":"Prevention and control of schistosomiasis and soil-transmitted helminthiasis","year":"2002","journal-title":"World Health Organization technical report series 912, i-vi"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S0074-02762011000200006","article-title":"Schistosoma mansoni: a method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails","volume":"106","author":"Couto","year":"2011","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jac\/19.1.87","article-title":"Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan","volume":"19","author":"Daneshmend","year":"1987","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1471-4922(01)02209-7","article-title":"Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal","volume":"18","author":"Danso-Appiah","year":"2002","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib9","series-title":"Drugs for Treating Schistosoma Mansoni Infection","first-page":"CD000528","author":"Danso-Appiah","year":"2013"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib10","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib11","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1017\/S0031182009000493","article-title":"Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs","volume":"136","author":"Doenhoff","year":"2009","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4269\/ajtmh.1967.16.483","article-title":"An improved perfusion technique for recovering adult schistosomes from laboratory animals","volume":"16","author":"Duvall","year":"1967","journal-title":"Am. J. Trop. Med. Hyg."},{"year":"2012","series-title":"Guideline on the Investigation of Drug Interactions","author":"EMA","key":"10.1016\/j.ijpddr.2023.01.003_bib13"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4269\/ajtmh.1994.51.83","article-title":"Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific","volume":"51","author":"Fallon","year":"1994","journal-title":"Am. J. Trop. Med. Hyg."},{"article-title":"Guidance for industry","year":"2020","series-title":"Vitro Drug Interaction Studies-Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions","key":"10.1016\/j.ijpddr.2023.01.003_bib3"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1124\/dmd.105.005033","article-title":"Direct determination of unbound intrinsic drug clearance in the microsomal stability assay","volume":"33","author":"Giuliano","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib16","first-page":"209","article-title":"Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal","volume":"46","author":"Gryseels","year":"1994","journal-title":"Trop. Geogr. Med."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib17","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0140-6736(06)69440-3","article-title":"Human schistosomiasis","volume":"368","author":"Gryseels","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008517","article-title":"An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans","volume":"14","author":"Guzman","year":"2020","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4269\/ajtmh.1999.60.932","article-title":"Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers","volume":"60","author":"Ismail","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib20","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1208\/ps040425","article-title":"Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?","volume":"4","author":"Ito","year":"2002","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/00498257209111048","article-title":"The metabolism of a new schistosomicide 2-isopropylaminomethyl-6-methyl-7-nitro-1,2,3,4-tetrahydroquinoline (UK 3883)","volume":"2","author":"Kaye","year":"1972","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/00034983.1976.11687128","article-title":"The metabolism of oxamniquine - a new schistosomicide","volume":"70","author":"Kaye","year":"1976","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib23","first-page":"359","article-title":"Oxamniquine pharmacokinetics in healthy Kenyan African volunteers","volume":"68","author":"Kokwaro","year":"1991","journal-title":"East Afr. Med. J."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/bdd.2510080106","article-title":"Method of residuals: estimation of absorption and elimination rate constants having comparable values","volume":"8","author":"Macheras","year":"1987","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008619","article-title":"Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: a randomized, non-inferiority clinical trial","volume":"14","author":"Mnkugwe","year":"2020","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib26","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.119.086496","article-title":"Regulatory recommendations for calculating the unbound maximum hepatic inlet concentration: a complicated story with a surprising and happy ending","volume":"47","author":"Parkinson","year":"2019","journal-title":"Drug Metab. Dispos."},{"year":"2018","series-title":"Guideline on Drug Interaction for Drug Development and Appropriate Provision of Information","key":"10.1016\/j.ijpddr.2023.01.003_bib28"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1021\/acsmedchemlett.8b00257","article-title":"Design, synthesis, and characterization of novel small molecules as broad range antischistosomal agents","volume":"9","author":"Rugel","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(06)70521-7","article-title":"Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk","volume":"6","author":"Steinmann","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib31","doi-asserted-by":"crossref","first-page":"11154","DOI":"10.1074\/jbc.M116.766527","article-title":"Structural and enzymatic insights into species-specific resistance to schistosome parasite drug therapy","volume":"292","author":"Taylor","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib32","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1126\/science.1243106","article-title":"Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites","volume":"342","author":"Valentim","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0001-706X(03)00029-9","article-title":"Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa","volume":"86","author":"van der Werf","year":"2003","journal-title":"Acta Trop."},{"year":"2016","series-title":"Fact Sheet: Schistosomiasis","key":"10.1016\/j.ijpddr.2023.01.003_bib34"},{"key":"10.1016\/j.ijpddr.2023.01.003_bib35","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4269\/ajtmh.1992.46.582","article-title":"Plasma pharmacokinetics and therapeutic efficacy of praziquantel and 4-hydroxypraziquantel in Schistosoma japonicum-infected rabbits after oral, rectal, and intramuscular administration","volume":"46","author":"Xiao","year":"1992","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2023.01.003_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003286","article-title":"Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials","volume":"8","author":"Zwang","year":"2014","journal-title":"PLoS Neglected Trop. Dis."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320723000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320723000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:51:43Z","timestamp":1761922303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320723000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":36,"alternative-id":["S2211320723000039"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2023.01.003","relation":{},"ISSN":["2211-3207"],"issn-type":[{"type":"print","value":"2211-3207"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}